CYCN Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion is advancing its portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are designed to target tissues of greatest relevance to the diseases they are intended to treat.

$2.45
As of 11/26/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/02/2019
Outstanding shares:  43,315,745
Average volume:  472,358
Market cap:   $114,786,724
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    23255M105
ISIN:        US23255M1053
Sedol:      
Valuation   (See tab for details)
PE ratio:   -1.77
PB ratio:   1.88
PS ratio:   32.40
Return on equity:   -72.52%
Net income %:   -1,154.11%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy